PPR-018 - Monotherapy versus dual lipid-lowering therapy in high-risk coronary artery disease patients

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-018
• By: WIRTH, Francesca
• Co-author(s): Ms Shanice Spiteri (Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta)
  Ms Marilyn Gauci (Department of Cardiology, Mater Dei Hospital, Msida, Malta)
  Ms Josette Desira (Department of Cardiology, Mater Dei Hospital, Msida, Malta)
  Dr Mark Abela (Department of Cardiology, Mater Dei Hospital, Msida, Malta)
  Dr Robert G. Xuereb (Department of Cardiology, Mater Dei Hospital, Msida, Malta)
  Dr Andrew Cassar Maempel (Department of Cardiology, Mater Dei Hospital, Msida, Malta)
  Professor Liberato Camilleri (Department of Statistics & Operations Research, Faculty of Science, University of Malta, Msida, Malta)
  Professor Lilian M. Azzopardi (Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta)
  Dr Francesca Wirth (Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta)
  
• Abstract:

  Background information: European Society of Cardiology guidelines recommend dual therapy with a high-intensity statin and ezetimibe if target low-density lipoprotein cholesterol (LDL-C) is not achieved with statin monotherapy. Ezetimibe is currently not available on the local government formulary and necessitates out-of-pocket payment by patients. ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login